RAFAEL FERREIRA COELHO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
conferenceObject Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.(2022) BASTOS, Diogo Assed; COELHO, Rafael; CARDILI, Leonardo; GALIZA, Felipe; ILARIO, Eder Nisi; VIANA, Ublio; MURTA, Claudio Bovolenta; GUGLIELMETTI, Giuliano; CORDEIRO, Mauricio; PONTES JR., Jose; MUNIZ, David Queiroz Borges; SILVA, Jamile Almeida; MOTA, Jose Mauricio; FREITAS, Guilherme Fialho De; LEITE, Katia Ramos Moreira; BUCHPIGUEL, Carlos Alberto; NAHAS, William CarlosconferenceObject CHRONOLOGY OF ENDOGENOUS TESTOSTERONE RECOVERY FOLLOWING ADT CESSATION - RESULTS FROM A PROSPECTIVE ANALYSIS(2023) NASCIMENTO, Bruno; PEDRENHO NETO, Rubens; ZANDONA, Pedro C. E.; BASTOS, Diogo Assed; COELHO, Rafael F.; BESSA JR., Jose; SANTANA, Feira De; NAHAS, William C.; HALLAK, Jorge; GOMES, Cristiano M.; MULHALL, John P.- Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study.(2017) LESTINGI, Jean Felipe Prodocimo; GUGLIELMETTI, Giuliano; PONTES JR., Jose; MITRE, Anuar Ibrahim; SARKIS, Alvaro; BASTOS, Diogo Assed; RIECHELMANN, Rachel; MATTEDI, Romulo Loss; CORDEIRO, Mauricio; COELHO, Rafael; SROUGI, Miguel; NAHAS, William Carlos
- The accuracy of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS v2 in disease upgrading on re-biopsy among patients with low-risk prostate cancer (PCa) on active surveillance (AS): A Brazilian perspective.(2017) VIANA, Pablio C. C.; HORVAT, Natally; GUGLIELMETTI, Giuliano; COELHO, Rafael; NAHAS, William Carlos; PARK, Rubens; BEZERRA, Regis; BASTOS, Diogo Assed; RODRIGUES, Thiana; VARGAS, Hebert Alberto
conferenceObject CHRONOLOGY OF ENDOGENOUS TESTOSTERONE RECOVERY FOLLOWING ANDROGEN DEPRIVATION THERAPY CESSATION - RESULTS FROM A PROSPECTIVE ANALYSIS(2023) NASCIMENTOL, B. C. G.; NETOL, R. Pedrenho; ZANDONAL, P.; BESSA, J. De; BASTOS, D.; CORDEIROL, M.; COELHOL, R.; NAHAS, W.; HALLAK, J.; MULHALL, J.; GOMES, C.- Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer(2020) BASTOS, Diogo A.; MATTEDI, Romulo L.; BARREIRO, Rodrigo; SANTOS, Filipe F. dos; BUZATTO, Vanessa; MASOTTI, Cibele; SOUZA, Jussara M.; LIMA, Mariana Z. T. de; FRIGUGLIETTI, Giulia W.; DZIK, Carlos; JARDIM, Denis L. F.; COELHO, Rafael; RIBEIRO FILHO, Leopoldo A.; CORDEIRO, Mauricio D.; NAHAS, William C.; MELLO, Evandro S. de; CHAMMAS, Roger; REIS, Luiz Fernando L.; BETTONI, Fabiana; GALANTE, Pedro A. F.; CAMARGO, Anamaria A.BACKGROUND: Optimal therapy for high-risk non-muscle invasive bladder cancer (NMIBC) includes intravesical instillation of Bacillus Calmette-Guerin (BCG). However, about 25-45% of patients do not benefit from BCG immunotherapy, and there is no biomarker to guide therapy. Also, many questions regarding BCG mechanisms of action remain unanswered. OBJECTIVE: To identify genomic biomarkers and characterize the underlying mechanism of benefit from BCG in NMIBC. PATIENTS AND METHODS: Pre-treatment archival index-tumors of 35 patients with NMIBC treated with BCG were analyzed by whole-exome sequencing (WES). Tumor mutation burden (TMB) and neoantigen load (NAL) were correlated with BCG response rate (RR) and recurrence-free survival (RFS). The presence of deleterious mutations in DNA damage response (DDR) genes was also compared between BCG-responsive (BCG-R, N= 17) and unresponsive (BCG-UR, N= 18) subgroups. RESULTS: TMB and NAL were higher in BCG-R compared to BCG-UR patients (median TMB 4.9 vs. 2.8 mutations/Mb, P = 0.017 and median NAL 100 vs. 65 neoantigens, P = 0.032). Improved RR and RFS were observed in patients with high vs. low TMB (RR 71% vs. 28%, P = 0.011 and mRFS 38.0 vs. 15.0 months, P = 0.009) and with high vs. low NAL (RR 71% vs. 28%, P = 0.011 and mRFS 36.0 vs. 18.5 months, P = 0.016). The presence of deleterious mutations in DDR genes was associated with improved RFS (mRFS 35.5 vs. 11.0 months, P = 0.017). CONCLUSIONS: In our cohort, improved outcomes after BCG immunotherapy were observed in patients with high TMB, high NAL and deleterious mutations in DDR genes. BCG may induce tumor-specific immune response by enhancing the recognition of neoantigens.
- Oncological outcomes of positive surgical margins in partial nephrectomy for renal cell carcinoma.(2017) NONEMACHER, Henrique T. S.; CORDEIRO, Mauricio; ALBUQUERQUE, George Lins De; GALUCCI, Fabio; CARVALHO, Paulo Afonso de; BORGES, Leonardo; GUGLIELMETTI, Giuliano Betuni; BASTOS, Diogo Assed; COELHO, Rafael; SARKIS, Alvaro; DZIK, Carlos; NAHAS, William Carlos
- Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence.(2019) VIANA, Publio; RODRIGUES, Thiana; MOTA, Davi Alves Martins; GUGLIELMETTI, Giuliano; BASTOS, Diogo Assed; FAZOLI, Arnaldo; NAHAS, William Carlos; COELHO, Rafael; CORDEIRO, Mauricio; HORVAT, Natally
- Can tumor contact length predict extracapsular extension, lymph node involvement, and biochemical recurrence?(2018) VIANA, Publio; RODRIGUES, Thiana; PACHANI, Danilo; HORVAT, Natally; CARVALHO, Arnaldo Fazoli; GUGLIELMETTI, Giuliano; COELHO, Rafael; BASTOS, Diogo Assed; NAHAS, William Carlos
conferenceObject A PROSPECTIVE ANALYSIS OF TESTOSTERONE (T) RECOVERY PROFILES AFTER NEOADJUVANT MAXIMAL ANDROGEN BLOCKADE IN HIGH-RISK LOCALIZED PROSTATE CANCER(2021) PEDRENHO NETO, Rubens; NASCIMENTO, Bruno C. G.; BASTOS, Diogo Assed; BESSA JUNIOR, Jose de; ILARIO, Eder Nisi; MURTA, Claudio Bovolenta; CORDEIRO, Mauricio Dener; COELHO, Rafael Ferreira; MULHALL, John P.; SROUGI, Miguel; NAHAS, William Carlos